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Supplementary Methods
CALIBER program: study data sources
The CALIBER1 (Cardiovascular disease research using Linked Bespoke studies and Electronic Records) research 
platform contains linked electronic health records from four data sources in England: 
1. Primary care data from 225 general practices in the Clinical Practice Research Datalink (CPRD).2 CPRD provides 
primary care data on demographics, ethnicity, health behaviours, diagnoses, investigations, procedures and 
prescriptions. Diagnoses are coded using the Read Clinical Terminology. (Read Terms are a major component of the 
SNOMED-CT terminology).
2. Hospital Episodes Statistics (HES), containing details of hospital admissions.3 Diagnoses are coded using the 
International Statistical Classification of Diseases and Health Related Problems, 10th revision (ICD-10); interventions 
are coded using the Office of the Population Censuses and Surveys Classification of Interventions and Procedures 
(OPCS). Ethnicity as recorded during hospital attendances is also included in HES. 
3. Details of acute coronary syndromes from the Myocardial Ischaemia National Audit Project registry (MINAP).4
4. Date and ICD-10 coded cause of death from the Office for National Statistics (ONS) death registry. The index of 
multiple deprivation according to the patient's area of residence was also obtained from ONS.5
Definition of diabetes
Patients were defined as diabetic at baseline (type 1, type 2 or uncertain type) based on coded diagnoses recorded in 
CPRD or HES on or before study entry (Figure S1). Lists of Read and ICD-10 diagnostic codes which convey diabetic 
status are curated on the CALIBER data portal (https://www.caliberresearch.org/portal/chapter/6).
The aim of this algorithm is to identify patients with type 2 diabetes. The majority of diabetic patients in this cohort 
have type 2 diabetes, and we are not aiming to identify all patients with type 1 diabetes (this algorithm would not be 
suitable for a study focusing on type 1 diabetes). Our algorithm does not use any information after study entry to 
classify patients, in order to reduce immortal time bias. However this bias is not eliminated completely because specific 
type 1 or type 2 codes may have been entered retrospectively only for patients who survived.
Our algorithm leaves many patients with an unclassified type of diabetes. However, rather than using a more complex 
algorithm, we carried out sensitivity analyses with different definitions (e.g. the type 2 definition or any diabetes).
Definition of endpoints
Cardiovascular phenotype definitions based on the CALIBER data sources are curated on the CALIBER data portal 
(www.caliberresearch.org/portal).
Stable angina was defined by a coded diagnosis in primary or secondary care of ischaemic chest pain or stable angina, a 
positive myocardial ischaemia test, two or more prescriptions of antianginal medication, or coronary revascularisation.
Unstable angina was defined as a primary or secondary care diagnosis of unstable angina, or an acute coronary 
syndrome without myocardial infarction recorded in the disease registry.
Coronary disease not further specified is a non-specific diagnosis of ischaemic or coronary heart disease in primary or 
secondary care that does not fall into one of the more specific categories. It was not included among the 12 diseases in 
the main displays of hazard ratios, but for cumulative incidence calculations it was combined with unstable angina.
Non-fatal myocardial infarction was defined as a disease registry diagnosis of an acute coronary syndrome with 
elevated troponin, or a primary or secondary care diagnosis of myocardial infarction.
Unheralded coronary death was death with the primary cause certified as coronary heart disease, and no prior history of 
cardiovascular disease. Patients with myocardial infarction who died on the day of their infarct were considered to have 
unheralded coronary death.
Heart failure was defined by coded diagnoses in primary care, secondary care and death certificates.
Arrhythmia or sudden cardiac death was a composite of ventricular arrhythmias, cardioversion procedures, implantable 
cardioverter defibrillator, and sudden cardiac death. It was defined using diagnoses and procedure codes in primary 
care, secondary care and death certificates.
Transient ischaemic attack was defined by coded diagnoses in primary or secondary care.
Ischaemic stroke was defined using coded diagnoses in primary care, secondary care and death certificates. Patients 
with a procedure code for carotid endarterectomy within 90 days of a stroke of unspecified type were considered to 
have ischaemic stroke.
'Stroke not further specified' is a diagnosis of stroke which does not state it is ischaemic or haemorrhagic. This clinical 
event was not included among the 12 diseases in the main displays of hazard ratios, but for cumulative incidence 
calculations it was combined with ischaemic stroke.
Subarachnoid haemorrhage was defined by coded diagnoses in primary care, secondary care and death certificates.
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Intracerebral haemorrhage was defined by coded diagnoses in primary care, secondary care and death certificates.
Peripheral arterial disease includes intermittent claudication, limb ischaemia or gangrene due to atherosclerotic disease 
in the arteries of the legs. It was defined by coded diagnoses and procedures in primary care, secondary care and death 
certificates.
Abdominal aortic aneurysm was defined by coded diagnoses and procedures in primary care, secondary care and death 
certificates.
Sample size
We used all eligible patients in the CALIBER database for this study. We carried out a power calculation for estimating 
the age-adjusted hazard ratio between type 2 diabetes and haemorrhagic stroke, one of the less common endpoints, 
using the powerSurvEpi package in R.6 Based on our dataset, with 1·8% of patients having type 2 diabetes and 
correlation coefficient between type 2 diabetes and age ρ² = 0·018, a sample size of 1 000 000 would give 76% power to 
detect a hazard ratio of 1·5 with a type I error rate of 5%, and a sample size of 1 500 000 would give 90% power.
Multiple imputation
Multiple imputation was implemented using the mice7 algorithm in the statistical package R, to replace missing values 
in exposure and risk factor variables. Imputation models were estimated separately for men and women and included:
1. All the baseline covariates used in the main analysis (age, quadratic age, sex, body mass index, deprivation, high 
density lipoprotein cholesterol, total cholesterol, systolic blood pressure, smoking status, statins and antihypertensive 
prescriptions); 
2. Prior (between 14 and 4 years before study entry) and post (between 0 and 1 year after study entry) averages of 
continuous covariates in the main analysis;  
3. Baseline measurements of covariates not considered in the main analysis (diastolic blood pressure, alcohol intake, 
white cell count, haemoglobin, creatinine, alanine aminotransferase);
4. Baseline medications (low-dose aspirin, loop diuretics, oral contraceptives and hormone replacement therapy);
5. Coexisting medical conditions (history of depression, cancer, renal disease, liver disease and chronic obstructive 
pulmonary disease); 
6. The Nelson-Aalen hazard and the event status for each endpoint analysed in the data.8
Non-normally distributed variables were log-transformed for imputation and exponentiated back to their original scale 
for analysis. Five multiply imputed datasets were generated, and Cox models were fitted to each dataset. Coefficients 
were combined using Rubin’s rules. The Kolmogorov-Smirnov test was used to compare the distribution of observed 
versus imputed log-transformed covariates. 
Survival analysis and competing risks
We carried out survival analysis to describe and model the first occurrence of any cardiovascular disease. A patient's 
follow-up ended when they experienced one of the cardiovascular endpoints or when they were censored. Subsequent 
events (e.g. MI occurring after stable angina) were not analysed.
To describe the incidence of each initial presentation over time we constructed cumulative incidence curves, taking into 
account the other possible initial presentations as competing events. Normal-based confidence intervals were 
constructed based on Greenwood's variance formula, as implemented in the R prodlim package.
For multivariable modellling we considered using Cox models (for modelling cause-specific hazards) or the Fine and 
Gray model (to compare cumulative incidence curves by modelling subdistribution hazards). As the aim of this study 
was observational epidemiology – to explore associations rather than predict risk – we considered cause specific hazard 
ratios to be appropriate quantities to estimate. They should be interpreted together with cumulative incidence curves but 
cannot be used to predict cumulative incidence. We also found the Fine and Gray model to be more computationally 
intensive, and it would require significant software engineering and/or computing time to apply it to the large dataset 
used in these analyses. We used follow-up time as the timescale for the Cox models.
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Supplementary Tables
Table S1. Inclusion criteria and endpoints in recent trials in type 2 diabetes
Components of primary outcome
Ref Author, year, study Intervention Inclusion criteria Exclusion criteria
Nonfatal 
MI
Nonfatal 
stroke
Cardio-
vascular 
death
Hospital-
ized heart 
failure
Unstable 
angina
9 ACCORD Study Group 2008
Intensive or 
standard HbA1c 
targets
1. Type 2 diabetes 
2. HbA1c ≥ 7·5% 
3. Either:
a. Aged 40-79 with cardiovascular disease, OR
b. Aged 55-79 with anatomical evidence of significant 
atherosclerosis, albuminuria, left ventricular hypertrophy, or 
at least two of: dyslipidemia, hypertension, current smoking, 
obesity.
Frequent or serious hypoglycaemic events, 
unwillingness to do home monitoring of 
glucose or inject insulin, BMI > 45 kg/m2, 
serum creatinine > 1·5 mg/dL, other serious 
illness
Yes Yes Yes
10 Parving 2012 (ALTITUDE)
Aliskiren versus 
placebo
1. Type 2 diabetes
2. Age ≥ 35
3. Microalbuminuria, macroalbuminuria, or eGFR 30-
60 mL/min/1·73m2 and MI, stroke, heart failure or coronary 
artery disease
Unstable serum creatinine, NHYA class III 
or IV heart 
failure, renal artery stenosis, malignancy in 
the past 5 years, valvular heart disease
Yes Yes Yes Yes
11 Green 2013 (TECOS)
Sitagliptin 
versus placebo
1. Type 2 diabetes
2. Age ≥ 50
3. HbA1c 6·5% to 8·0%
4. History of MI, ischaemic stroke, revascularisation, carotid 
stenosis, or peripheral arterial disease
5. On a stable dose of insulin or oral antidiabetic drugs
Liver cirrhosis, severe hypoglycaemia, life 
expectancy < 2 years,
eGFR < 30 mL/min/1·73m2
Yes Yes Yes Yes
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Scirica 2013 
(SAVOR-TIMI 
53)
Saxagliptin 
versus placebo
1. Type 2 diabetes
2. HbA1c 6·5% to 12·0%
3. Either:
a. Age ≥ 40 and ischaemic heart disease, peripheral vascular 
disease or ischaemic stroke, OR
b. Age ≥ 55 (men) or 60 (women) and dyslipidemia, 
hypertension, or smoking
Life expectancy < 5 years, MI or stroke 
within the past 2 months, renal transplant or 
dialysis, HIV, long term oral steroid 
treatment, BMI > 50 kg/m2, sustained BP > 
180/100 mmHg
Yes Yes Yes
13 Home 2007 (RECORD)
Rosiglitazone 
versus 
metformin and 
sulphonylurea
1. Type 2 diabetes
2. Aged 40-75 years
3. BMI > 25 kg/m2
4. HbA1c 7·0% to 9·0% while on maximum dose of 
sulphonylurea or metformin
Use of other antidiabetic drugs, major 
cardiovascular event in previous 3 months, 
heart failure, renal impairment, uncontrolled 
hypertension
Yes Yes Yes Yes Yes
14 Young 2009 (DIAD)
Screening for 
coronary artery 
disease
1. Onset of type 2 diabetes at age 30 years or older with no 
history of ketoacidosis 
2. Age 50-75 at enrollment
History of coronary disease or angina, 
limited life expectancy Yes Yes
Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration rate; MI, myocardial infarction
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Table S2. Age and sex-specific prevalence of diabetes recorded in CALIBER at study entry
The total number of patients was 2 135 617, and included patients with pregnancy or prior history of cardiovascular 
disease which were excluded in the main analysis.
Percentage of patients with diabetes mellitus at baseline (95% CI)
Sex Age group
Number of 
patients Any diabetes Type 1 diabetes Type 2 diabetes
Diabetes of unspecified 
type
Men 30–40 420 975 0·87 (0·85–0·90) 0·47 (0·45–0·49) 0·28 (0·26–0·30) 0·13 (0·12–0·14)
40–50 215 607 2·25 (2·19–2·32) 0·50 (0·47–0·53) 1·37 (1·32–1·42) 0·38 (0·36–0·41)
50–60 170 679 4·41 (4·32–4·51) 0·45 (0·42–0·48) 3·24 (3·16–3·33) 0·73 (0·69–0·77)
60–70 119 507 8·31 (8·15–8·46) 0·52 (0·48–0·56) 6·32 (6·18–6·46) 1·47 (1·40–1·54)
70–80 80 614 10·5 (10·3–10·8) 0·53 (0·48–0·58) 7·89 (7·71–8·08) 2·12 (2·03–2·23)
≥80 38 991 9·96 (9·66–10·3) 0·39 (0·33–0·46) 7·32 (7·06–7·58) 2·25 (2·10–2·40)
Women 30–40 411 996 0·77 (0·74–0·80) 0·35 (0·33–0·37) 0·25 (0·23–0·26) 0·17 (0·16–0·19)
40–50 198 619 1·52 (1·47–1·57) 0·34 (0·31–0·37) 0·90 (0·86–0·95) 0·28 (0·25–0·30)
50–60 166 467 2·90 (2·82–2·98) 0·34 (0·31–0·37) 2·03 (1·96–2·10) 0·53 (0·49–0·56)
60–70 123 553 5·79 (5·66–5·93) 0·36 (0·33–0·40) 4·37 (4·26–4·49) 1·06 (1·00–1·11)
70–80 103 284 7·82 (7·66–7·98) 0·42 (0·38–0·46) 5·70 (5·56–5·84) 1·70 (1·62–1·78)
≥80 85 325 7·69 (7·51–7·87) 0·31 (0·27–0·35) 5·59 (5·43–5·74) 1·79 (1·71–1·88)
Table S3. Distribution of events, time to event and age at event for initial presentation of cardiovascular disease 
among patients with no diabetes or type 2 diabetes
No diabetes (107 501 events) Type 2 diabetes (6137 events)
Initial presentation of 
cardiovascular disease
% of 
events
Median time to 
event (years)
Median age at 
event (years) % of events
Median time to 
event (years)
Median age at 
event (years)
Stable angina 11·4 3·2 67·0 11·9 2·5 68·6
Unstable angina   4·9 4·5 63·1   4·0 2·8 64·7
Coronary disease not further specified   9·3 4·4 67·3 10·2 3·3 67·4
Non-fatal myocardial infarction 14·1 4·7 66·7 11·5 3·4 71·1
Unheralded coronary death   4·7 5·1 76·2   4·2 4·1 77·0
Heart failure 12·2 3·6 79·8 14·1 3·1 76·9
Arrhythmia or sudden cardiac death   3·0 5·0 67·1   1·6 4·0 68·3
Transient ischaemic attack 10·2 4·0 74·3   8·4 3·4 75·2
Ischaemic stroke   5·2 5·5 76·4   5·1 4·0 76·0
Stroke not further specified   9·4 3·4 79·7 10·3 2·5 78·3
Subarachnoid haemorrhage   1·2 4·4 57·3   0·2 2·8 74·4
Intracerebral haemorrhage   2·1 4·8 74·0   1·4 4·2 74·7
Peripheral arterial disease   9·4 4·4 70·1 16·2 3·5 71·7
Abdominal aortic aneurysm   2·8 5·0 76·2   1·0 4·5 77·8
Overall 100·0  4·2 72·0 100·0  3·2 72·6
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Table S4. Cumulative incidence of initial presentation of cardiovascular diseases at age 80 for patients with type 
2 diabetes or no diabetes at age 40
Cumulative incidences expressed as percentages (95% CI), taking into account risk of competing events
Women Men
Cardiovascular disease initially 
presenting as: No diabetes Type 2 diabetes No diabetes Type 2 diabetes
Stable angina 4·5 (4·4–4·6) 10·1 (8·7–11·5) 5·7 (5·5–5·8) 9·5 (8·4–10·7)
Unstable angina or coronary disease not 
further specified 5·2 (5·1–5·3) 11·6 (10·0–13·2) 7·1 (6·9–7·3) 13·1 (11·7–14·5) 
Non-fatal myocardial infarction 3·4 (3·3–3·5) 6·0 (4·9–7·2) 8·0 (7·8–8·1) 11·4 (9·9–12·8)
Unheralded coronary death 0·9 (0·9–1·0) 1·5 (0·9–2·0) 2·2 (2·1–2·3) 2·4 (1·9–2·9)
Heart failure 3·3 (3·1–3·4) 6·4 (5·4–7·3) 3·7 (3·6–3·9) 6·1 (5·2–6·9)
Arrhythmia or sudden cardiac death 0·9 (0·8–1·0) 0·7 (0·4–1·0) 1·7 (1·6–1·8) 1·8 (1·2–2·4)
Transient ischaemic attack 3·6 (3·5–3·7) 4·1 (3·3–4·9) 3·8 (3·7–3·9) 3·9 (3·3–4·6)
Ischaemic or unspecified stroke 3·9 (3·8–4·1) 7·3 (6·2–8·5) 4·7 (4·6–4·9) 6·1 (5·3–6·9)
Subarachnoid haemorrhage 0·6 (0·5–0·6) 0·2 (0·0–0·4) 0·3 (0·3–0·4) 0·0 (0·0–0·1)
Intracerebral haemorrhage 0·7 (0·6–0·7) 0·4 (0·2–0·6) 0·8 (0·7–0·8) 0·8 (0·5–1·1)
Peripheral arterial disease 3·2 (3·1–3·3) 9·7 (8·4–11·1) 4·5 (4·4–4·7) 11·7 (10·5–13·0)
Abdominal aortic aneurysm 0·5 (0·5–0·6) 0·1 (0·0–0·2) 1·7 (1·6–1·8) 0·6 (0·4–0·8)
All cardiovascular presentations 30·7 (30·3–31·0) 58·2 (54·9–61·4) 44·3 (43·8–44·7) 67·4 (64·4–70·4)
Death from other causes without any 
cardiovascular disease prior to death 14·7 (14·5–15·0) 12·4 (11·0–13·8) 16·4 (16·2–16·6) 11·9 (10·7–13·1)
Table S5. Hazard ratios obtained by analyses using different levels of adjustment
Initial presentation
Primary analysis (adjusted for age, sex, 
risk factors, statins and 
antihypertensives)
Adjusted for age, sex and 
risk factors
Adjusted for age and sex 
only
Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Hazard ratio 
(95% CI) P value
Stable angina 1·62 (1·49–1·77) < 0·0001 1·79 (1·64–1·95) < 0·0001 1·93 (1·79–2·08) < 0·0001
Unstable angina 1·53 (1·32–1·76) < 0·0001 1·71 (1·49–1·97) < 0·0001 1·84 (1·62–2·10) < 0·0001
Coronary disease not further specified 1·58 (1·45–1·73) < 0·0001 1·93 (1·76–2·11) < 0·0001 2·11 (1·95–2·29) < 0·0001
Non-fatal myocardial infarction 1·54 (1·42–1·67) < 0·0001 1·50 (1·38–1·62) < 0·0001 1·57 (1·46–1·70) < 0·0001
Unheralded coronary death 1·43 (1·23–1·65) < 0·0001 1·39 (1·20–1·60) < 0·0001 1·48 (1·31–1·68) < 0·0001
Heart failure 1·56 (1·45–1·69) < 0·0001 1·58 (1·47–1·70) < 0·0001 1·80 (1·68–1·93) < 0·0001
Arrhythmia or sudden cardiac death 0·95 (0·76–1·19) 0·65 0·99 (0·80–1·24) 0·94 1·12 (0·92–1·37) 0·26
Transient ischaemic attack 1·45 (1·31–1·60) < 0·0001 1·40 (1·27–1·55) < 0·0001 1·42 (1·30–1·55) < 0·0001
Ischaemic stroke 1·72 (1·52–1·95) < 0·0001 1·68 (1·49–1·91) < 0·0001 1·72 (1·53–1·93) < 0·0001
Stroke not further specified 1·64 (1·48–1·81) < 0·0001 1·64 (1·48–1·82) < 0·0001 1·77 (1·63–1·92) < 0·0001
Subarachnoid haemorrhage 0·48 (0·26–0·89) 0·020 0·48 (0·26–0·89) 0·020 0·45 (0·25–0·81) 0·0077
Intracerebral haemorrhage 1·28 (1·02–1·62) 0·035 1·18 (0·94–1·49) 0·15 1·20 (0·97–1·50) 0·099
Peripheral arterial disease 2·98 (2·76–3·22) < 0·0001 3·07 (2·84–3·32) < 0·0001 3·14 (2·94–3·35) < 0·0001
Abdominal aortic aneurysm 0·46 (0·35–0·59) < 0·0001 0·49 (0·38–0·63) < 0·0001 0·52 (0·40–0·67) < 0·0001
Other death 1·10 (1·05–1·17) 0.0004 1·01 (0·96–1·07) 0·70 1·04 (0·992–1·09) 0·11
All analyses used the complete dataset with multiple imputation of missing covariate values. 'Risk factors' comprised 
body mass index, deprivation, high density lipoprotein cholesterol, total cholesterol, systolic blood pressure and 
smoking status.
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Table S6. Hazard ratios from complete case analyses
Initial presentation Adjusted for age, sex, risk factors, statins and antihypertensives
Adjusted for age, sex and risk 
factors Adjusted for age and sex only
Hazard ratio 
(95% CI) P value
Hazard ratio 
(95% CI) P value
Hazard ratio 
(95% CI) P value
Stable angina 2·03 (1·59–2·60) < 0·0001 2·10 (1·65–2·67) < 0·0001 2·10 (1·67–2·64) < 0·0001
Unstable angina 1·16 (0·78–1·73) 0·45 1·28 (0·87–1·88) 0·22 1·19 (0·83–1·72) 0·34
Coronary disease not further 
specified 1·64 (1·30–2·07) < 0·0001 1·69 (1·35–2·13) < 0·0001 1·75 (1·41–2·16) < 0·0001
Non-fatal myocardial infarction 1·50 (1·17–1·93) 0·0016 1·49 (1·16–1·90) 0·0018 1·48 (1·17–1·88) 0·0011
Unheralded coronary death 2·22 (1·43–3·46) 0·0004 1·93 (1·24–3·02) 0·0038 1·73 (1·16–2·59) 0·0070
Heart failure 3·01 (2·22–4·07) < 0·0001 2·96 (2·19–3·99) < 0·0001 3·29 (2·48–4·35) < 0·0001
Arrhythmia or sudden cardiac 
death 0·92 (0·49–1·73) 0·79 0·88 (0·47–1·63) 0·68 0·83 (0·46–1·51) 0·55
Transient ischaemic attack 1·33 (0·97–1·81) 0·076 1·27 (0·93–1·73) 0·13 1·20 (0·89–1·61) 0·23
Ischaemic stroke 1·61 (1·05–2·46) 0·028 1·57 (1·03–2·40) 0·034 1·47 (0·98–2·19) 0·060
Stroke not further specified 1·16 (0·83–1·64) 0·39 1·14 (0·81–1·60) 0·46 1·22 (0·88–1·69) 0·23
Subarachnoid haemorrhage – – – – – –
Intracerebral haemorrhage 1·20 (0·55–2·63) 0·66 1·15 (0·53–2·50) 0·73 0·93 (0·45–1·93) 0·85
Peripheral arterial disease 3·05 (2·40–3·88) < 0·0001 3·16 (2·50–4·01) < 0·0001 2·80 (2·24–3·49) < 0·0001
Abdominal aortic aneurysm 0·30 (0·14–0·67) 0·0034 0·30 (0·14–0·65) 0·0026 0·31 (0·14–0·66) 0·0026
Other death 1·63 (1·38–1·93) < 0·0001 1·53 (1·29–1·80) < 0·0001 1·45 (1·24–1·69) < 0·0001
These analyses were limited to the subset of individuals with completely recorded covariate information: 59 116 with 
no diabetes and 12 411 with type 2 diabetes. 'Risk factors' comprised body mass index, deprivation, high density 
lipoprotein cholesterol, total cholesterol, systolic blood pressure and smoking status.
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Table S7. Hazard ratios from secondary analyses
Initial presentation Patients with any diabetes versus no diabetes
Type 2 diabetes versus no diabetes, restricted 
to patients entering study after 2004
Hazard ratio 
(95% CI) P value Hazard ratio (95% CI) P value
Stable angina 1·70 (1·57–1·83) < 0·0001 1·62 (1·17–2·23) 0·0030
Unstable angina 1·66 (1·47–1·87) < 0·0001 1·30 (0·86–1·95) 0·21
Coronary disease not further specified 1·73 (1·60–1·87) < 0·0001 1·33 (1·03–1·73) 0·031
Non-fatal myocardial infarction 1·74 (1·62–1·86) < 0·0001 1·48 (1·14–1·91) 0·0031
Unheralded coronary death 1·81 (1·60–2·04) < 0·0001 1·93 (1·31–2·84) 0.00098
Heart failure 1·76 (1·65–1·87) < 0·0001 2·02 (1·55–2·63) < 0·0001
Arrhythmia or sudden cardiac death 1·16 (0·97–1·39) 0.11 1·10 (0·58–2·06) 0·78
Transient ischaemic attack 1·54 (1·42–1·68) < 0·0001 1·24 (0·91–1·69) 0·18
Ischaemic stroke 1·72 (1·54–1·92) < 0·0001 1·42 (1·00–2·01) 0·051
Stroke not further specified 1·80 (1·65–1·95) < 0·0001 1·24 (0·99–1·56) 0·059
Subarachnoid haemorrhage 0·54 (0·33–0·89) 0·016 – –
Intracerebral haemorrhage 1·40 (1·15–1·70) 0·0007 1·10 (0·53–2·27) 0·80
Peripheral arterial disease 3·33 (3·12–3·55) < 0·0001 2·70 (2·12–3·44) < 0·0001
Abdominal aortic aneurysm 0·49 (0·39–0·62) < 0·0001 0·33 (0·15–0·72) 0·0056
Other death 1·39 (1·33–1·45) < 0·0001 1·46 (1·29–1·64) < 0·0001
Hazard ratios were adjusted for age, sex, risk factors (body mass index, deprivation, high density lipoprotein 
cholesterol, total cholesterol, systolic blood pressure, smoking status), and statin and antihypertensive prescription in 
the year before study entry.
Table S8. Hazard ratios for composite endpoints
Endpoint Adjusted for age, sex, risk factors, statins and antihypertensives
Adjusted for age, sex and 
risk factors
Adjusted for age and sex 
only
Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Hazard ratio 
(95% CI) P value
Cardiovascular death 1·53 (1·45–1·62) < 0·0001 1·62 (1·53–1·71) < 0·0001 1·72 (1·64–1·81) < 0·0001
Non-cardiovascular death 1·29 (1·24–1·34) < 0·0001 1·22 (1·17–1·26) < 0·0001 1·25 (1·21–1·29) < 0·0001
Death due to any cause 1·35 (1·31–1·39) < 0·0001 1·31 (1·27–1·36) < 0·0001 1·36 (1·32–1·40) < 0·0001
All analyses used the complete dataset with multiple imputation of missing covariate values. 'Risk factors' comprised 
body mass index, deprivation, high density lipoprotein cholesterol, total cholesterol, systolic blood pressure and 
smoking status.
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Supplementary Figures
Figure S1. Patient flow diagram and classification of 
baseline diabetes status
The aim of this algorithm is to identify patients with type 2 
diabetes. The majority of diabetic patients in this cohort have 
type 2 diabetes, and we are not aiming to identify all patients 
with type 1 diabetes (this algorithm would not be suitable for a 
study focusing on type I diabetes). Our algorithm does not use 
any information after study entry to classify patients, in order 
to reduce immortal time bias. However this bias is not 
eliminated completely because specific type 1 or type 2 codes 
may have been entered retrospectively only for patients who 
survived.
Our algorithm leaves many patients with an unclassified type 
of diabetes. However, rather than using a more complex 
algorithm, we carried out sensitivity analyses with different 
definitions (e.g. the type 2 definition or any diabetes).
Lists of Read and ICD-10 diagnostic codes which convey 
diabetic status are curated on the CALIBER data portal 
(https://www.caliberresearch.org/
portal/chapter/6).
A. CALIBER phenotype algorithm for diabetes
B. Patient flow diagram
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Figure S2. Association of type 2 diabetes with initial presentation of cardiovascular diseases using different 
adjustments
'Risk factors' adjustment includes age, sex, body mass index, deprivation, high density lipoprotein cholesterol, total 
cholesterol, systolic blood pressure, and smoking status. 'Treatment' includes statins and antihypertensive prescription in 
the year before study entry. P values *** < 0·001, ** < 0·01, * < 0·05
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Figure S3. Adjusted hazard ratios for type 2 diabetes and initial presentations of cardiovascular diseases by age 
group
Hazard ratios by age group for the association of different initial presentations of cardiovascular disease with type 2 
diabetes, adjusted for sex, body mass index, deprivation, high density lipoprotein cholesterol, total cholesterol, systolic 
blood pressure, smoking status, statins and antihypertensive prescriptions. P values *** < 0·001, ** < 0·01, * < 0·05
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Figure S4. Association of type 2 diabetes with initial presentation of cardiovascular diseases by level of glycaemic 
control.
Hazard ratios for initial presentations of cardiovascular diseases associated with type 2 diabetes with different levels of 
HbA1c (mean in mmol/mol within 3 years of baseline), compared with no diabetes, adjusted for age, sex, body mass 
index, deprivation, high density lipoprotein cholesterol, total cholesterol, systolic blood pressure, smoking status, statins 
and antihypertensive prescriptions. P values *** < 0·001, ** < 0·01, * < 0·05
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Figure S5. Association of type 2 diabetes with initial presentation of cardiovascular diseases using different 
subsets of the data sources.
Hazard ratios adjusted for age, sex, body mass index, deprivation, high density lipoprotein cholesterol, total cholesterol, 
systolic blood pressure, smoking status, statins and antihypertensive prescriptions. P values *** < 0·001, ** < 0·01, * < 
0·05
13
Figure S6. Schoenfeld residuals and tests for proportional hazards
Scaled Shoenfeld residuals for type 2 diabetes versus no diabetes, adjusted for age, sex, body mass index, deprivation, 
high density lipoprotein cholesterol, total cholesterol, systolic blood pressure, smoking status, statins and 
antihypertensive prescriptions. The lines show the estimate and 95% confidence interval for the beta coefficient for type 
2 diabetes over time. The top left corner of each graph contains ρ, χ² and p value for the correlation between 
transformed survival time and scaled Schoenfeld residuals. For clarity, points plotted on the graph are for a random 
sample of 20 000 patients rather than all 1.9 million.
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